Oncopeptides announces year-end cash 2021
STOCKHOLM — January 5, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces a financial update after the restructuring of the company, following the withdrawal of Pepaxto[® ](INN melphalan flufenamide) from the US market.The cash position at year-end 2021 was approximately SEK 360 M. This figure is preliminary, and the formal reporting of the cash position will be part of the year-end report 2021, to be released on February 17, 2022. Oncopeptides has taken